- Micron Exits Chinese Data Center Market Amid Trade Conflict 조선일보
- Exclusive: Micron to exit server chips business in China after ban, sources say Reuters
- Micron Stock Slips From Record High Amid China Business Concerns—Watch These Key…
Category: 6. Business
-

Micron Exits Chinese Data Center Market Amid Trade Conflict – 조선일보
-

Will 3M’s (MMM) Indonesia Manufacturing Deal Redefine Its Energy Sector Growth Story?
-
PT Pipa Mas Putih recently announced a partnership with 3M to manufacture 3M™ Ceramic Sand Screens in Indonesia, combining 3M’s global technology with local production to serve high-pressure energy applications.
-
This collaboration is…
Continue Reading
-
-

EROAD (NZSE:ERD) Is Down 31.9% After Guidance Cut and North American Impairments – What’s Changed
-
In a recent announcement, EROAD downgraded its fiscal 2026 revenue guidance, reported up to NZ$150 million in North American asset impairments, and outlined a renewed focus on Australia and New Zealand alongside scaled-back North American…
Continue Reading
-
-

Pembrolizumab Plus Lenvatinib Shows Encouraging Efficacy in Uveal Melanoma | Targeted Oncology
The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) elicited promising progression-free survival (PFS) outcomes in patients with uveal melanoma who were both HLA-A*02:01–negative and –positive with a manageable safety…
Continue Reading
-

Assessing Celestica (TSX:CLS) Valuation After Strong Share Price Surge
Celestica (TSX:CLS) shares have moved recently, catching the attention of investors interested in tech services and manufacturing. The company’s strong performance this year prompts a closer look at what is driving returns.
See our latest…
Continue Reading
-

Examining Valuation After Recent 6% Stock Climb
Open Text (NasdaqGS:OTEX) stock has caught some attention in recent weeks, thanks in part to a steady uptick of 6% over the past month. Investors seem interested in the company’s consistent revenue and growing net income.
See our latest…
Continue Reading
-

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors
A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma…
Continue Reading
-

Targeted therapy combination shows superior outcomes in advanced kidney cancer
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type…
Continue Reading
-

Sac-TMT Improves PFS in HR+/HER2– Metastatic Breast Cancer | Targeted Oncology
The TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT; SKB264; MK-2870) yielded superior progression-free survival (PFS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic…
Continue Reading
-

Objective’s (ASX:OCL) five-year total shareholder returns outpace the underlying earnings growth
Passive investing in index funds can generate returns that roughly match the overall market. But in our experience, buying the right stocks can give your wealth a significant boost. For example, the Objective Corporation Limited (ASX:OCL)…
Continue Reading